In clinical settings, a meta-analysis showed an obvious trend of reduction in mortality rates in HMGCoA reductase inhibitor users from 2005 to 2013, as a consequence of their pleiotropic and antioxidant effects [ 39 ], supporting the hypothesis that HMGCoA reductase inhibitors may improve survival in HFpEF [ 40 ].
1
—
—